166 related articles for article (PubMed ID: 29771769)
21. BCL10 as a useful marker for pancreatic acinar cell carcinoma, especially using endoscopic ultrasound cytology specimens.
Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
Pathol Int; 2013 Mar; 63(3):176-82. PubMed ID: 23530562
[TBL] [Abstract][Full Text] [Related]
22. Pancreatic acinar cell carcinomas with prominent ductal differentiation: Mixed acinar ductal carcinoma and mixed acinar endocrine ductal carcinoma.
Stelow EB; Shaco-Levy R; Bao F; Garcia J; Klimstra DS
Am J Surg Pathol; 2010 Apr; 34(4):510-8. PubMed ID: 20182344
[TBL] [Abstract][Full Text] [Related]
23. Survival and prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas: comparison with pancreatic ductal adenocarcinoma.
Woo SM; Ryu JK; Lee SH; Yoo JW; Park JK; Kim YT; Yoon YB
Pancreas; 2008 Jan; 36(1):50-5. PubMed ID: 18192881
[TBL] [Abstract][Full Text] [Related]
24. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
[TBL] [Abstract][Full Text] [Related]
25. Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets.
Witkiewicz AK; McMillan EA; Balaji U; Baek G; Lin WC; Mansour J; Mollaee M; Wagner KU; Koduru P; Yopp A; Choti MA; Yeo CJ; McCue P; White MA; Knudsen ES
Nat Commun; 2015 Apr; 6():6744. PubMed ID: 25855536
[TBL] [Abstract][Full Text] [Related]
26. FOLFIRINOX as first-line treatment for unresectable acinar cell carcinoma of the pancreas: a case report.
Schempf U; Sipos B; König C; Malek NP; Bitzer M; Plentz RR
Z Gastroenterol; 2014 Feb; 52(2):200-3. PubMed ID: 24526405
[TBL] [Abstract][Full Text] [Related]
27. Serine protease inhibitor Kazal type 1 and epidermal growth factor receptor are expressed in pancreatic tubular adenocarcinoma, intraductal papillary mucinous neoplasm, and pancreatic intraepithelial neoplasia.
Ozaki N; Ohmuraya M; Ida S; Hashimoto D; Ikuta Y; Chikamoto A; Hirota M; Baba H
J Hepatobiliary Pancreat Sci; 2013 Aug; 20(6):620-7. PubMed ID: 23475261
[TBL] [Abstract][Full Text] [Related]
28. Dramatic Response to Carboplatin Plus Paclitaxel in Pancreatic Mucinous Cystadenocarcinoma with Liver Metastasis.
Oda N; Tabata M; Uno M; Umeda Y; Kato H; Kubo T; Senoo S; Yagi T; Fujiwara T; Maeda Y; Kiura K
Intern Med; 2021 Sep; 60(18):2967-2971. PubMed ID: 33814494
[TBL] [Abstract][Full Text] [Related]
29. Platinum-based therapy in adenosquamous pancreatic cancer: experience at two institutions.
De Souza AL; Saif MW
JOP; 2014 Mar; 15(2):144-6. PubMed ID: 24618440
[TBL] [Abstract][Full Text] [Related]
30. Tracking the Clonal Evolution of Adenosquamous Carcinoma, a Rare Variant of Intraductal Papillary Mucinous Neoplasm of the Pancreas.
Matsuzaka S; Karasaki H; Ono Y; Ogata M; Oikawa K; Tamakawa S; Chiba S; Muraki M; Yokochi T; Funakoshi H; Kono T; Nagashima K; Mizukami Y
Pancreas; 2016 Jul; 45(6):915-8. PubMed ID: 27295533
[TBL] [Abstract][Full Text] [Related]
31. Update on the molecular pathogenesis of pancreatic tumors other than common ductal adenocarcinoma.
Antonello D; Gobbo S; Corbo V; Sipos B; Lemoine NR; Scarpa A
Pancreatology; 2009; 9(1-2):25-33. PubMed ID: 19077452
[TBL] [Abstract][Full Text] [Related]
32. [Pathologic characteristics and evaluation of the pancreatic cancer].
Fukushima N; Mukai K
Gan To Kagaku Ryoho; 2005 May; 32(5):599-604. PubMed ID: 15918557
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological features of adenosquamous pancreatic cancer.
Regi P; Butturini G; Malleo G; Pedica F; D'Onofrio M; Bassi C
Langenbecks Arch Surg; 2011 Feb; 396(2):217-22. PubMed ID: 20617336
[TBL] [Abstract][Full Text] [Related]
34. [Pathological analysis of pancreatic colloid carcinoma in 7 cases].
Min X; Guo JZ; Zhan Q
Zhonghua Zhong Liu Za Zhi; 2007 May; 29(5):377-8. PubMed ID: 17892136
[No Abstract] [Full Text] [Related]
35. Morphological study of 391 cases of exocrine pancreatic tumours with special reference to the classification of exocrine pancreatic carcinoma.
Chen J; Baithun SI
J Pathol; 1985 May; 146(1):17-29. PubMed ID: 2989468
[TBL] [Abstract][Full Text] [Related]
36. The prognosis of intraductal papillary mucinous tumors of the pancreas.
Yamao K; Ohashi K; Nakamura T; Suzuki T; Shimizu Y; Nakamura Y; Horibe Y; Yanagisawa A; Nakao A; Nimuara Y; Naito Y; Hayakawa T
Hepatogastroenterology; 2000; 47(34):1129-34. PubMed ID: 11020896
[TBL] [Abstract][Full Text] [Related]
37. The genetic classification of pancreatic neoplasia.
Matthaei H; Semaan A; Hruban RH
J Gastroenterol; 2015 May; 50(5):520-32. PubMed ID: 25605630
[TBL] [Abstract][Full Text] [Related]
38. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
[TBL] [Abstract][Full Text] [Related]
39. Comparison of carcinoembryonic antigen and molecular analysis in pancreatic cyst fluid.
Sawhney MS; Devarajan S; O'Farrel P; Cury MS; Kundu R; Vollmer CM; Brown A; Chuttani R; Pleskow DK
Gastrointest Endosc; 2009 May; 69(6):1106-10. PubMed ID: 19249035
[TBL] [Abstract][Full Text] [Related]
40. Acinar cell carcinoma of the pancreas: a rare disease with different diagnostic and therapeutic implications than ductal adenocarcinoma.
Kruger S; Haas M; Burger PJ; Ormanns S; Modest DP; Westphalen CB; Kleespies A; Angele MK; Hartwig W; Bruns CJ; Kirchner T; Werner J; Heinemann V; Boeck S
J Cancer Res Clin Oncol; 2016 Dec; 142(12):2585-2591. PubMed ID: 27629876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
